Trade-Ideas LLC identified

Pfizer

(

PFE

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Pfizer as such a stock due to the following factors:

  • PFE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $982.2 million.
  • PFE traded 3.0 million shares today in the pre-market hours as of 9:14 AM, representing 10.6% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PFE with the Ticky from Trade-Ideas. See the FREE profile for PFE NOW at Trade-Ideas

More details on PFE:

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The stock currently has a dividend yield of 3.3%. PFE has a PE ratio of 24. Currently there are 10 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

The average volume for Pfizer has been 26.7 million shares per day over the past 30 days. Pfizer has a market cap of $210.7 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.07 and a short float of 1.2% with 2.56 days to cover. Shares are up 12.3% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Pfizer as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:

  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period, despite the company's weak earnings results. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • Regardless of the drop in revenue, the company managed to outperform against the industry average of 4.5%. Since the same quarter one year prior, revenues slightly dropped by 2.2%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • The gross profit margin for PFIZER INC is currently very high, coming in at 74.25%. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, PFE's net profit margin of 17.61% compares favorably to the industry average.
  • PFIZER INC's earnings per share declined by 19.0% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past year. However, we anticipate this trend reversing over the coming year. During the past fiscal year, PFIZER INC reported lower earnings of $1.42 versus $1.65 in the prior year. This year, the market expects an improvement in earnings ($2.10 versus $1.42).
  • The change in net income from the same quarter one year ago has exceeded that of the Pharmaceuticals industry average, but is less than that of the S&P 500. The net income has decreased by 20.1% when compared to the same quarter one year ago, dropping from $2,666.00 million to $2,129.00 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.